Ceftizoxime
|
|
|
- CAS-Nr.
- 68401-81-0
- Englisch Name:
- Ceftizoxime
- Synonyma:
- Cefimx;Ceftizox;EPOCELIN;FR-13749;Ceftisomin;CEFTIZOXIME;Ceftizoxime >CEFTIZOXIME ACID;Ceftizoxime (350 mg);Ceftizoxime, ≥ 98.0%
- CBNumber:
- CB1717299
- Summenformel:
- C13H13N5O5S2
- Molgewicht:
- 383.4
- MOL-Datei:
- 68401-81-0.mol
|
Ceftizoxime Eigenschaften
- Schmelzpunkt:
- 227° (dec)
- Dichte
- 1.89±0.1 g/cm3(Predicted)
- storage temp.
- under inert gas (nitrogen or Argon) at 2–8 °C
- L?slichkeit
- Aqueous Base (Slightly), DMSO (Slightly, Heated), Methanol (Slightly, Heated, Sonicated)
- Aggregatzustand
- Solid
- pka
- pKa 2.1 (Uncertain)
- Farbe
- White to Pale Yellow
- Merck
- 14,1951
- Stabilit?t:
- Hygroscopic
- InChIKey
- NNULBSISHYWZJU-LLKWHZGFSA-N
- SMILES
- N12[C@@]([H])([C@H](NC(/C(/C3=CSC(N)=N3)=N\OC)=O)C1=O)SCC=C2C(O)=O
- CAS Datenbank
- 68401-81-0(CAS DataBase Reference)
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| RTECS-Nr. |
XI0367375 |
|
|
| HS Code |
2941906000 |
|
|
| Toxizit?t |
LD50 intravenous in rat: 8gm/kg |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
|
| Sicherheit |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P302+P352 |
BEI BERüHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckm??ig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
| P332+P313 |
Bei Hautreizung: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen. |
| P337+P313 |
Bei anhaltender Augenreizung: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen. |
|
Ceftizoxime Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
In ceftizoxime, the whole C-3 side chain has been omitted to prevent deactivation by hydrolysis. It rather
resembles cefotaxime in its properties; however, not being subject to metabolism, its pharmacokinetic
properties are much less complex.
Verwenden
Ceftizoxime is used for bacterial infections of the lower respiratory tract, infections of the
urinary tract, infections of the bones, joints, skin, soft tissues, and abdominal infections.
Synonyms of this drug are ceftix and eposerin.
Definition
ChEBI: A parenteral third-generation cephalosporin, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7beta-position.
Antimicrobial activity
A semisynthetic cephalosporin supplied as the sodium salt. The
properties are very similar to those of cefotaxime, but it lacks
the acetoxymethyl group at position C-4 and is therefore not
subject to deacetylation. Activity against common pathogenic
bacteria (Table 13.4) is very similar to that of cefotaxime.
A 500 mg intramuscular injection achieves a plasma concentration
of around 14 mg/L. A concentration of 85–90 mg/L
is produced 30 min at the end of a 30-min intravenous infusion.
The plasma half-life is 1.3–1.9 h. Protein binding is
30%. It is well distributed. In children with meningitis receiving
200–250 mg/kg per day in four equally divided doses for
14–21 days, mean CSF concentrations 2 h after a dose were
6.4 mg/L on day 2 and 3.6 mg/L on day 14.
About 70–90% of the dose is recovered in the urine in the first
24 h, principally by glomerular filtration. Probenecid increases
the plasma half-life by about 50%. In patients receiving 1 g
intravenously over 30 min, the plasma elimination half-life rose
to 35 h when the corrected creatinine clearance was <10 mL/
min. It is partly removed by peritoneal and hemodialysis.
Adverse reactions and clinical use are similar to those of
cefotaxime.
Ceftizoxime Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Ceftizoxime Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 221)Lieferanten
68401-81-0()Verwandte Suche:
2,4-Pentandion
N,N'-Ethylenbis[N-acetylacetamid]
4,4-Bis(4-hydroxyphenyl)valeriansure
4,4'-Diacetylbiphenyl
Benzothiazol
3,4-Dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-benzopyran-6-ol
Reaktionsgemisch, bestehend aus5-Chlor-2-methyl-2H-isothiazol-3-on und 2-Methyl-2H-isothiazol-3-on (3:1)
4-(Diethylamino)salicylaldehyd
5-Chlorvaleriansaeure
Pralmorelin
Acetylchlorid
Ethyl-N-acetyl-L-tyrosinat
Sauerstoff
2-Aminothiazol
Ceftizoxime alapivoxil
Ceftizoxime sodium
Ceftazidim
Cefotaxim-natrium
- (6R,7R)-7-[(Z)-2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetylamino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- (6R,7R)-7α-[2-(2-Imino-4-thiazolin-4-yl)-2-[(Z)-methoxyimino]acetylamino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- Ceftizox
- (7R)-7-[[2-(2-Aminothiazole-4-yl)-2-(methoxyimino)-1-oxoethyl]amino]cepham-3-ene-4-carboxylic acid
- (7R)-7β-[2-(2-Amino-4-thiazolyl)-2-(methoxyimino)acetylamino]cepham-3-ene-4-carboxylic acid
- Ceftizoxime (350 mg)I0E2620.999mg/mg(an)
- Ceftizoxime (350 mg)
- (6R,7R)-7-[(2Z)-2-(2-aMino-1,3-thiazol-4-yl)-2-(MethoxyiMino)acetaMido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- EPOCELIN
- CEFTIZOXIME
- CEFTIZOXIME ACID
- (6r-(6-alpha,7-beta(z)))-l)(methoxyimino)acetyl)amino)-8-oxo
- 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-(((2-amino-4-thiazoly
- 7-Amino-3-[[[2,5-Dihydro-6-Hydroxy-2-Methyl-5-Oxo-1,2,4-Trizin-3-Yl]-Thio]Methyl]-Cephalosporanic Acid
- 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, [6R-[6α,7β(Z)]]-
- 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, (6R,7R)-
- Ceftisomin
- syn-7-(2-(2-amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carbo xyli
- (6R,7R)-7-[[(2Z)-(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- Cefimx
- FR-13749
- [(6R-[6α，7β(Z)])-7-[[(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct2-ene-2-carboxylie acid
- (6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-methoxyimino-1-oxoethyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- Ceftizoxime Ceftizoxime
- Ceftizoxime >
- 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-8-oxo-, (6R,7R)-
- Ceftizoxime USP/EP/BP
- (6R,7R)-7-((Z)-2-(2-Aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- Ceftizoxime (1098173)
- 1,2-Benzenedicarboxylicacid,bis(8-methylbutyl)ester
- Ceftizoxime, ≥ 98.0%
- 68401-81-0
- 68041-82-1
- C13H13N5O5S2
